Company gains access to SSI’s method for producing stable isotope-labeled biochemicals.

Cambridge Isotope Laboratories (CIL) reports the take-over of the Spectra Stable Isotopes (SSI) division of Spectra Gases. “This acquisition expands and complements CIL’s product portfolio of biochemicals and reagents for use within the biomolecular NMR and mass spec research communities,” remarks Maureen Duffy, CIL’s vp of sales and marketing.

CIL supplies stable isotopes for research applications in proteomics, genomics, molecular biology, metabolic research, clinical and diagnostic research, and ultratrace environmental analysis. SSI is produces stable isotope-labeled biochemicals including growth media for bacterial, yeast, insect, and mammalian cell culture, RNA and DNA derivatives for oligonucleotide synthesis, fatty acids, carbohydrates, and amino acids.   

With this transaction, CIL acquires SSI’s methodology for stable isotope-labeled biochemicals and plans to continue to offer the full range of SSI products.

Previous articleNew Protein Linked to the Spread of Prostate Cancer to the Bones
Next articleScientists Image Prostate Cancer as It Spreads to Lymph Nodes